Polynovo Limited · ASX:PNV
Polynovo — Investor Presentation (December 2017)
22 slides from Polynovo's investor presentation, Dec 14, 2017
Slide 1: Hong Kong Investor Presentation
PolyNovo Limited ABN 96 083 866 862 2/320 Lorimer Street Port Melbourne VIC Australia 3207 For personal use only P +61 (0) 3 8681 4050 F +61 (0) 3 8681 4099 14 December 2017 Hong Kong Investor Presentation PolyNovo Limited is pleased to release the presentation to be given by CEO Paul Brennan and Ch
Slide 2: Hong Kong Investors
For personal use only Hong Kong Investors 14 December 2017 ASX: PNV
Slide 3: Disclaimer
Disclaimer For personal use only ASX : PNV This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representa
Slide 4: PolyNovo Board
For personal use only PolyNovo Board Page 3
Slide 5: PolyNovo Management
PolyNovo Management For personal use only PolyNovo – Corporate Video See www.polynovo.com.au Page 4
Slide 6: Corporate Overview
Corporate Overview For personal use only Holder Shares % Holding 1. THE TRUST COMPANY (AUSTRALIA) LIMITED 54,500,000 8.33 2. HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED 40,462,364 6.19 3. CITICORP NOMINEES PTY LIMITED 15,705,313 2.40 4. DR JOHN EDWARD GREENWOOD 13,377,118 2.05 5. LATERAL INNOVATIONS P
Slide 7: NovoSorb Polymer, a unique platform technology
NovoSorb™ Polymer , a unique platform technology For personal use only NovoSorb • Developed by the CSIRO and spun out as PolyNovo. Listed on the ASX 2004 • Unique polymer technology, Carbamate, that is programmable for re-absorbsion rate and product attributes • Excellent biocompatibility, safety an
Slide 8: First product commercial sales: NovoSorb BTM
First product commercial sales: NovoSorb BTM For personal use only BTM is a fully synthetic, biodegradable dermal matrix with 3 layers: • Sealing membrane A temporary, transparent, polyurethane sealing membrane designed to physiologically ‘close’ the wound limiting water loss/evaporation • Bonding l
Slide 9: NovoSorb BTM Application and Integration
NovoSorb BTM Application and Integration How it works For personal use only Video – How NovoSorb BTM works See www.polynovo.com.au 1. Wound surgically debrided and BTM stapled into place…wound is ‘physiologically closed’, limiting contraction and risk of infection. 2. Cellular and vascular integrati
Slide 10: Sales strategies
Sales strategies For personal use only • Direct sales team in US Revenue to date FY18 ( as at 8 December 2017) – Currently 5 with expansion to 8 anticipated in 2018 as sales revenues build • Australia/New Zealand transition to a direct sales team early 2018 $894,231 • South Africa support partner Su
Slide 11: NovoSorb BTM Sales in US
NovoSorb BTM Sales in US For personal use only • US FDA 510(k) approved product- on sale now in the US • NovoSorb BTM sales with repeat orders established in multiple US hospitals • Direct sales team of 5 with further expansion anticipated as sales revenues continue to ramp up • Surgeon experience p
Slide 12: NovoSorb BTM on Sale – other markets
NovoSorb BTM on Sale – other markets For personal use only South Africa and other African Countries • Ascendis Medical subsidiary, Surgical Innovations, is our exclusive distributor • 5 dedicated BTM sales representatives, experienced in the plastic/burn surgery segment • Initial sales focus is the
Slide 13: Long term follow up, publication
Long term follow up, publication For personal use only Professor John Greenwood , Royal Adelaide Hospital, and his team have completed the long term follow up of the first 5 burn patients. • Publication in a global peer review journal • Excellent outcomes for all patients with their NovoSorb BTM tre
Slide 14: Outcomes of the first five burn patients
Outcomes of the first five burn patients For personal use only Pt 1 Day 536 Pt 2 Day 368 Pt 3 Day 312 Pt 4 Day 171 Pt 5 Day 194 Page 13
Slide 15: CE Mark Trial Update
CE Mark Trial Update For personal use only A CE Mark is a regulatory standard/requirement for many countries eg: Europe, Australia, SE-Asia. Clinical trails are required as part of a Class III certification Working concurrently on Priority Review pathway with the TGA for ARTG /CE application. If suc
Slide 16: BARDA PMA Trial Programs
BARDA PMA Trial Programs For personal use only BARDA is a US Federal agency within the Department of Human & Health Services. They are charged with preparing for mass disaster management. BARDA awarded PolyNovo a contract which funds our US based clinical trials program. Success in these trials will
Slide 17: NovoSorb Platform Technology Market Opportunities
NovoSorb Platform Technology Market Opportunities For personal use only PNV market opportunities in ~ $7B + Hernia~ $2B + market Other product possibilities in progress Entry~2019 Diabetes cellular depot Bone Void Filler Drug Elution dermal pellet ~$2.3B market Pelvic floor Breast ~$3B market Licenc
Slide 18: New Business opportunities
New Business opportunities For personal use only NovoSorb platform technology Breast Market ~$3B • PolyNovo has signed a MOU with a global medical device company for the development of a range of breast product. Currently working through the contracting process. These include – a reinforcement “brea
Slide 19: Capital raising completed October 2017
Capital raising completed October 2017 For personal use only PolyNovo has completed a Use of new capital $7M capital raising via • Expanding sales and support infrastructure to private placement at $0.27 accelerate sales, focused on the US market – Sales staff, Clinical support role and marketing pr
Slide 20: Expanded cleanroom production facility
Expanded cleanroom production facility- New For personal use only Page 19
Slide 21: Video Links
Video Links For personal use only • https://www.youtube.com/channel/UCL-B7V8ImJxqDmKiHpmY-TA • http://www.finnewsnetwork.com.au/MediaCenter/MediaCenterMobile.aspx?Site=FNN1074 • http://polynovo.com.au/
Slide 22: First patient treated with NovoSorb BTM
For personal use only JW 1st patient treated with NovoSorb BTM